Today: 19 May 2026
Imperial Brands share price drops nearly 2% in London trade as buyback rolls on, tobacco bill in focus
24 February 2026
1 min read

Imperial Brands share price drops nearly 2% in London trade as buyback rolls on, tobacco bill in focus

London, Feb 24, 2026, 09:24 GMT — Regular session

  • Imperial Brands slipped 1.8% at the open, erasing a slice of Monday’s advance.
  • Late Monday, the company announced it’s buying back more shares for cancellation.
  • This week, UK lawmakers kick off another round of debate over tobacco and vaping regulations.

Imperial Brands (IMB.L) dipped 1.8% to 3,241 pence right after the open in London on Tuesday, down from Monday’s 3,300 pence close. Shares kicked off the session at 3,308 pence, touching a low of 3,234 as 168,138 shares changed hands. That leaves the stock sitting nearly 3% under its Feb. 6, 52-week high of 3,341 pence.

Investors are weighing cash returns against regulatory risks as the UK’s Tobacco and Vapes Bill hits its report stage in the House of Lords this Tuesday. Lawmakers will get their chance to push through changes, picking apart the bill one clause at a time.

Tobacco shares can swing sharply, even when little’s happening. Imperial remains pegged to its dividends and buybacks, with regulation always lurking in the background.

Imperial reported Monday it bought back 597,332 ordinary shares for cancellation, paying an average of 3,264.45 pence apiece. Prices in the trades ranged from 3,219.00 to 3,296.00 pence. The company noted these purchases are part of its ongoing £1.45 billion share repurchase programme. Once settled and cancelled, Imperial will have 789,357,100 shares in issue, excluding treasury shares.

Shares of British American Tobacco (BATS.L) slipped 0.4% to 4,579 pence in early deals.

Buybacks boil down to basic math: with fewer shares in play, earnings per share get a boost—even if overall profit holds steady. Still, when sentiment sours or the only thing moving is the price itself, that won’t keep traders from putting pressure on the stock.

“Report stage” might sound technical, but markets pay close attention since it can reshape a bill in a hurry. When it comes to tobacco, amendments at this point could bring stricter marketing limits, shift how enforcement works, or push back compliance deadlines.

Politics isn’t a one-way street here. The bill might end up tougher than investors are bracing for—or it could stall out entirely. Both scenarios throw a wrench into predicting legal volumes and pricing.

Imperial has its final dividend set for March 31, with a trading update following on April 14. Traders are keeping an eye on any news emerging from the Lords debate before shifting focus to that April update, looking for a clearer sense of momentum.

Stock Market Today

  • Top 5 Blue-Chip Stocks to Boost Portfolio Returns in 2026
    May 19, 2026, 9:58 AM EDT. The Dow Jones Industrial Average briefly surpassed 50,000 in May, highlighting positive momentum supported by its position above key moving averages. Analysts recommend five blue-chip stocks with strong Zacks Rank #2 (Buy) ratings to enhance portfolios in 2026: Cisco Systems (CSCO), Salesforce (CRM), Apple (AAPL), Visa (V), and Chevron (CVX). Cisco benefits from robust AI infrastructure demand and restructuring to focus on growth areas. Salesforce is expanding generative AI offerings through Einstein GPT and strategic investments. These stocks are favored for potential revenue and earnings growth amid evolving technological and economic trends.

Latest articles

Bakkt Up Early After Director Buys $4.85M in Shares

Bakkt Up Early After Director Buys $4.85M in Shares

19 May 2026
Bakkt shares jumped 14.2% to $9.96 in pre-market trading Tuesday after a filing showed director Michael Alfred’s vehicle bought $4.85 million in stock. SEC documents said Alfred acquired 585,000 shares last week via Alpine Fox LP. CEO Akshay Naheta exercised options for 33,557 shares at $10 each. Bakkt recently reported Q1 revenue of $243.6 million, down sharply from a year earlier.
Relay Therapeutics Shares Rise In Pre-Market Ahead Of Key Drug Update

Relay Therapeutics Shares Rise In Pre-Market Ahead Of Key Drug Update

19 May 2026
Relay Therapeutics shares jumped 11.3% to $13.47 in premarket trading Tuesday after reporting a 60% volumetric response rate in 20 evaluable patients from its Phase 2 trial of zovegalisib for vascular anomalies. The company said 95% of patients saw some lesion reduction at 12 weeks. No patients discontinued due to adverse events. The regular Nasdaq session was set to open at 9:30 a.m. ET.

Popular

Nasdaq Futures Slip Pre-Nvidia Results

Nasdaq Futures Slip Pre-Nvidia Results

19 May 2026
Nasdaq 100 futures dropped 0.51%, S&P 500 futures fell 0.30%, and Dow futures slipped 0.11% early Tuesday as tech shares retreated ahead of Nvidia’s earnings. Monday’s session saw the Nasdaq down 0.51%, S&P 500 off 0.07%, and the Dow up 0.32%. Brent crude traded at $110.50 a barrel. Investors watched for key earnings from Nvidia, Home Depot, and Walmart this week.
Haleon PLC share price slips ahead of FY 2025 results as investors eye guidance
Previous Story

Haleon PLC share price slips ahead of FY 2025 results as investors eye guidance

American Express stock tumbles 7% as “AI scare trade” hits payments; what to watch before the open
Next Story

American Express stock tumbles 7% as “AI scare trade” hits payments; what to watch before the open

Go toTop